Skip to main content
Premium Trial:

Request an Annual Quote

Ligon Discovery to Screen Candidates for Bayer Schering

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ligon Discovery today said that it will use its Small Molecule Microarray (SMM) screening platform to discover candidates for Bayer Schering Pharma's drug development programs.

The Cambridge, Mass.-based firm said that its technology works by affixing drug candidates to a slide, enabling it to use cell lysates, instead of "developing a complex assay based on a full understanding of a protein target's functions."

This method allows it to screen every protein in an entire target class or every protein in a disease pathway, the firm said.

"Our partnership with Bayer Schering Pharma provides the opportunity to demonstrate the unique capabilities of SMM, particularly to screen challenging targets and identify unique starting points for drug development," Ligon Discovery CEO Christian Bailey said in a statement.

Financial terms of the agreement were not released.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.